Share Print
Main content
Research news

Research on Alzheimer's disease and neurodegenerative diseases is steadily progressing. In this section you will find various news items that make up the current news in this field, in Switzerland and around the world.


Professor Giacobini is a regular contributor to the BHR website, writing reviews of scientific articles related to Alzheimer's disease.

Pr.Ezio Giacobino

Professor Ezio Giacobini obtained his PhD in cellular neuropharmacology from the Karolinska Institute (Sweden) in 1959. In 1995, he became Associate Professor in the Department of Rehabilitation and Geriatrics at the Faculty of Medicine of the University of Geneva and Assistant Professor of Pharmacology, Psychiatry and Neurology at the Southern Illinois School of Medicine (USA). His main research interests are in the preclinical and clinical development of drug therapies for Alzheimer's disease. He received the Life time achievement award in Alzheimer's disease research from the Alzheimer's Association (USA) at the 8th International Conference on Alzheimer's Disease in Stockholm in 2002.

The role of lipids in the development of Alzheimer’s disease

A European consortium coordinated by UNIGE shows how a mutation in the APOE protein changes the lipid transport in the brain and could promote the arise of Alzheimer’s disease.


The probabilistic model of Alzheimer disease: The amyloid hypothesis revised

A proposal for a probabilistic model, in which amyloid would remain a key player, but as one of several risk factors.

Blood biomarkers: a promising new avenue for large-scale screening for Alzheimer's disease

A recent study allowed researchers to assess the level of concordance between lumbar puncture, positron emission tomography and blood tests. 

CLAMP* project: acoustic and visual stimulation to reduce amyloid

The aim of the CLAMP project is to determine whether multisensory stimulation at 40 Hz can reduce the amount of amyloid in the brain of people who have high levels of this protein.

RECAGE: a European project on specialised medical care

RECAGE aims to measure the efficiency of a medical care unit specialising in the care of patients with behavioural and psychological disorders related to dementia.

Long term effects of cholinesterase inhibitors on cognitive decline and mortality

The effect of cholinesterase inhibitors (CHIs) is considered to be mainly symptomatic and relatively short-lived (6 months to one year).

Dernière mise à jour : 24/06/2021